Lilly CEO: 70% of New Senior GLP-1 Patients Choose Lilly Drugs, Foundayo Takes One-Third of Oral Market
LLY sits 62% above its 52-week low of $712.05.
Summary
CEO Dave Ricks disclosed that 70% of the 700,000 seniors newly on GLP-1 treatments since Medicare's July coverage decision are using Lilly's medications, with Foundayo capturing one-third of new oral GLP-1 patients. This follows the FDA approval of Foundayo and the Medicare Bridge program enabling $50 co-pays. Lilly also broke ground on a $6.5B Houston API plant to manufacture Foundayo and other drugs, supporting domestic supply and international expansion. Guggenheim raised Foundayo 2027/2028 sales forecasts to $1.8B and $3.7B, citing strong early launch trends. The commentary confirms rapid commercial traction in the obesity market and capacity investment to meet demand.
At the time of this announcement, LLY was trading at $1,152.28 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $712.05 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.